Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Evgen Pharma RNS Release

Total Voting Rights


RNS Number : 7759A
Evgen Pharma PLC
02 January 2018
 

 

 

 

2 January 2018

 

 

 

 

 

 

 

Evgen Pharma plc

 

 ("Evgen Pharma" or "the Company")

 

Total Voting Rights

 

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, makes the following notification in accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1.

As at 29 December 2017 the Company's issued share capital consists of 93,276,858 Ordinary Shares of 0.25p each.

The total number of voting rights in the Company is 93,276,858 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Enquiries

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

c/o +44 (0) 20 7466 5000

 



Buchanan

Mark Court, Sophie Wills, Stephanie Watson

+44 (0) 20 7466 5000

 



Northland Capital Partners Limited

Matthew Johnson, Gerry Beaney (Corporate Finance)

John Howes, Rob Rees (Corporate Broking)

+44 (0) 20 3861 6625




 

Notes for editors

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRDLLFBVFFZBBL

Evgen Pharma Timeline

Article
October 21 2015

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use